TAS::75 0849::TAS SBIR TOPIC 277 - PHASE I SNAPMAPTM: A FUNCTIONAL COMPANION DIA

目前用于治疗决策的大多数预测生物标记物提供了有关药物靶点的存在或不存在的信息，但很少揭示药物也必须影响的信号网络的功能电路。体外生物标记物是从患者体内移除的活肿瘤细胞中诱发的动态分子标记物。这些体外生物标志物提供了有价值的机制信息，可能有助于药物开发和指导临床靶向治疗药物的选择。我们建议开发一种配套的诊断测试，名为SnapMap，针对针对ErbB信号转导网络的药物。这项测试将利用在SnapPath肿瘤处理系统上处理的肿瘤活检样本，从活体肿瘤样本中唤起体外生物标记物。

Most of the currently utilized predictive biomarkers for therapeutic decision-making provide information about the presence or absence of the drug target, but reveal little about the functional circuitry of the signaling network that the drug must also impact. Ex vivo biomarkers are dynamic molecular markers evoked from living tumor cells after removal from the patient. Such ex vivo biomarkers provide valuable mechanistic information that may facilitate drug development and guide the clinical selection of targeted therapeutics. We propose to develop a companion diagnostic test, named SnapMap, for drugs targeting the ErbB signal transduction network. This test will utilize tumor biopsy samples processed on the SnapPath¿ tumor processing system to evoke ex vivo biomarkers from live tumor samples.